Indefinite-Lived Research and Development Assets
Pfizer Indefinite-Lived Research and Development Assets decreased by 2.6% to $21.64B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.8%, from $19.35B to $21.64B. Over 5 years (FY 2020 to FY 2025), Indefinite-Lived Research and Development Assets shows an upward trend with a 37.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
Detailed definition
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Peer comparison
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assetsHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.54B | $4.50B | $4.43B | $9.92B | $9.83B | $9.63B | $13.16B | $12.86B | $12.40B | $12.39B | $24.78B | $22.93B | $22.65B | $22.65B | $19.56B | $19.35B | $18.67B | $17.81B | $22.22B | $21.64B |
| QoQ Change | — | -0.8% | -1.5% | +123.9% | -0.9% | -2.0% | +36.6% | -2.2% | -3.6% | -0.0% | +100.0% | -7.5% | -1.2% | +0.0% | -13.6% | -1.1% | -3.5% | -4.6% | +24.8% | -2.6% |
| YoY Change | — | — | — | — | +116.7% | +114.0% | +196.8% | +29.6% | +26.1% | +28.7% | +88.4% | +78.3% | +82.7% | +82.7% | -21.1% | -15.6% | -17.5% | -21.4% | +13.6% | +11.8% |
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Pfizer's indefinite-lived research and development assets?
- Pfizer (PFE) reported indefinite-lived research and development assets of $21.64B in Q1 2026.
- How has Pfizer's indefinite-lived research and development assets changed year-over-year?
- Pfizer's indefinite-lived research and development assets increased by 11.8% year-over-year, from $19.35B to $21.64B.
- What is the long-term trend for Pfizer's indefinite-lived research and development assets?
- Over 5 years (2020 to 2025), Pfizer's indefinite-lived research and development assets has grown at a 37.2% compound annual growth rate (CAGR), from $4.58B to $22.22B.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects acquired from other companies that are not yet ready for sale.